Grünenthal GmbH
German family-owned pharmaceutical company focused primarily on pain management.
Last updated August 25, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Grünenthal GmbH is a privately held German pharmaceutical company headquartered in Aachen. Founded in 1946 by Hermann Wirtz Sr. as Chemie Grünenthal, it has remained family-owned and developed from a postwar chemicals and medicines business into an international pharmaceutical group with a strong concentration on pain treatment. The company operates through German offices and subsidiaries or commercial structures in Europe, Latin America, the United States and China. One of Grünenthal's earliest commercial successes came after the Allied Control Council lifted restrictions that had prevented German companies from researching and manufacturing penicillin. Grünenthal became the first company to introduce penicillin to the postwar German market, providing an important financial foundation for later expansion. The company subsequently built businesses in several therapeutic areas, including pain, gynecology, dermatology and anti-infective medicines, although pain has become its defining area of expertise. Grünenthal's history is inseparable from the thalidomide disaster. Under research director Heinrich Mückter, the company synthesized thalidomide in the 1950s and marketed it in Germany from 1957 as Contergan. It was promoted primarily as a sedative and as a treatment for morning sickness, despite the absence of appropriate testing in pregnant women. The medicine caused miscarriages, infant deaths and severe congenital disabilities in many countries. It was withdrawn from the market in late 1961 after the connection with birth defects became clear. The episode led to criminal proceedings against company executives, a major public controversy, compensation arrangements and significant strengthening of pharmaceutical regulation in West Germany. Grünenthal paid funds to the Contergan Foundation in 1970 and announced an additional voluntary contribution in 2008. In 2012, the company issued its first formal public apology to victims and their mothers. After the thalidomide period, Grünenthal concentrated increasingly on prescription medicines, especially analgesics. Its portfolio has included tramadol under the Tramal name, the transdermal pain product Transtec, the capsaicin product Qutenza and tapentadol-related medicines. The company has combined internal research with licensing, acquisitions and portfolio transactions. Notable expansion included the acquisition of Thar Pharmaceuticals in 2016, the creation of the US-based Averitas Pharma structure following the acquisition of US rights for Qutenza, and later purchases involving established products such as Crestor, Nebido, Grünenthal Meds and Movantik. The company describes its research priorities as including peripheral neuropathic pain, chronic postoperative pain, osteoarthritis and chronic back pain. It has also supported medical education and research through the Grünenthal Foundation for Palliative Medicine and the EFIC-Grünenthal Grant. These activities reflect a corporate positioning built around pain science, specialty medicines and long-term family ownership. Grünenthal remains an active pharmaceutical company, but public information about its current ownership structure, financial performance and leadership roster is limited compared with that of publicly traded peers.
History
Grünenthal was established in 1946 in Stolberg, Rhineland, as Chemie Grünenthal GmbH by Hermann Wirtz Sr. The company entered the postwar German medicines market at a time when Allied restrictions had limited German pharmaceutical research and manufacturing. After those restrictions were lifted, Grünenthal introduced penicillin into Germany, becoming the first company to do so in the postwar period. The resulting commercial success helped finance subsequent research and product development. The headquarters were later moved to Aachen, and the company continued under family ownership. The company's most consequential and damaging chapter began with thalidomide. Research under Heinrich Mückter produced the compound in 1954, and Grünenthal obtained a patent. The substance was initially included in a combination medicine for respiratory infections and was later marketed as Contergan, a sedative that was also promoted for morning sickness. At the time, regulatory systems did not generally require the kind of reproductive and teratogenicity testing now expected, and no suitable clinical program was conducted in pregnant women. Thalidomide was subsequently licensed or supplied to companies in numerous countries under different brand names. Reports of unusual congenital deformities began appearing in Germany in the late 1950s. The cause was not immediately recognized, but by late 1961 investigators had linked the injuries to Contergan and the product was withdrawn. The drug caused fetal deaths, miscarriages and severe disabilities, particularly limb deformities, among children exposed during pregnancy. The US Food and Drug Administration did not approve thalidomide, although limited quantities entered the country through investigational channels. The scandal became a defining event in pharmaceutical history and contributed to stronger medicine-testing requirements and institutional changes in West Germany, including the creation of a Federal Ministry of Health in 1962. Grünenthal executives faced a criminal trial beginning in 1968. The proceedings ended in 1970 after the indictment was closed on grounds that included limited culpability and insufficient public interest in continuing the case. That year, Grünenthal paid DM100 million to the Contergan Foundation for Disabled People, while the German government contributed additional funds. The company later resisted further payments for many years, but in 2008 announced a voluntary contribution of €50 million to support the foundation. In 2012, chief executive Harald Stock delivered the company's first public apology for its failure to establish a personal relationship with victims and their mothers. Disputes over compensation, including claims brought by Spanish victims, continued to attract criticism. Thalidomide was later found to have therapeutic value in some conditions. In 1964, Jacob Sheskin reported its beneficial effect in leprosy, particularly for painful inflammatory reactions. From the 1970s, Grünenthal supplied tablets to leprosy clinics under controlled arrangements involving the World Health Organization. The company later stopped exporting the medicine in some circumstances because of liability and insurance concerns. During the later twentieth century, Grünenthal diversified into pain management and other therapeutic fields. It developed or commercialized tramadol, marketed as Tramal, which became one of the best-known opioid analgesics. Its portfolio also included Transtec, a transdermal pain patch, Belara in gynecology and products in dermatology and anti-infectives. The company supported palliative-care infrastructure through a foundation launched in 1998 and began the EFIC-Grünenthal Grant in 2004 to support young pain researchers. In the twenty-first century, Grünenthal increasingly combined research with external innovation and acquisitions. It acquired Thar Pharmaceuticals in 2016 and obtained rights to products including Qutenza, a capsaicin treatment for neuropathic pain. Averitas Pharma was developed as a US commercial platform. Later transactions expanded its established-medicines portfolio: Crestor was acquired from AstraZeneca in 2020, Nebido from Bayer in 2022, a portfolio from Kyowa Kirin in 2023 and Valinor with Movantik in 2024. The company has stated that its research focus includes peripheral neuropathic pain, chronic postoperative pain, osteoarthritis and chronic back pain, including newer approaches such as cell therapy. Grünenthal has also faced modern compliance criticism. In 2010, a UK industry-code case found that promotional material for Versatis breached the applicable code because it encouraged off-label use and used a flawed cost comparison. A separate allegation concerning promotion of unlicensed tapentadol was investigated by the company and reported as unsubstantiated. Grünenthal remains an active, privately held pharmaceutical company with pain management at the center of its business.
- 2024
Valinor and Movantik are acquired
[1]Grünenthal expands its established-products business by acquiring Valinor and Movantik.
- 2022
Nebido is acquired
[1]The company acquires Nebido from Bayer for treatment of hypogonadism.
- 2020
Crestor is acquired
[1]Grünenthal acquires the cholesterol-lowering medicine Crestor from AstraZeneca.
- 2018
Averitas Pharma platform is developed
[1]Grünenthal builds a US commercial structure around Qutenza following rights acquisitions.
- 2016
Thar Pharmaceuticals is acquired
[1]Grünenthal expands its pain-related business through the acquisition of Thar Pharmaceuticals.
- 2008
Additional voluntary contribution announced
[1]The company announces a €50 million contribution to the Thalidomide Foundation.
- 1998
Palliative-care foundation is launched
[1]Grünenthal establishes the Grünenthal Foundation for Palliative Medicine.
- 1970
Initial Contergan Foundation payment
[1]Grünenthal pays DM100 million to the Contergan Foundation; the criminal indictment is also closed.
- 1968
Criminal trial begins
[1]Grünenthal executives are tried in connection with the thalidomide disaster.
- 1961
Contergan is withdrawn
[1]The link between thalidomide exposure and severe fetal harm is recognized, and the medicine is removed from the market.
Products and positioning
A family-owned international pharmaceutical company specializing in pain management and adjacent specialty medicines, with a business model combining proprietary research, licensing, acquisitions and established-product commercialization.
Pain medicine
Tramal
Tramal is Grünenthal's brand for tramadol-based analgesic products. Tramadol became one of the company's most commercially important pain medicines and is used for the treatment of moderate to moderately severe pain. Its opioid-related pharmacology has made prescribing controls, abuse potential and responsible use important parts of the product's regulatory context.
Transdermal analgesic
Transtec
Transtec is a transdermal pain patch based on buprenorphine. It is designed to deliver analgesic treatment through the skin over an extended period and forms part of Grünenthal's long-standing pain-management portfolio. Availability and indications can differ by market.
Neuropathic-pain treatment
Qutenza
Qutenza is a high-concentration capsaicin cutaneous patch used in the management of certain peripheral neuropathic pain conditions. Grünenthal obtained rights to the product in several markets and built the Averitas Pharma structure to support US commercialization.
Gynecology
Belara
Belara is an oral contraceptive in Grünenthal's gynecology portfolio. It illustrates the company's historical activity outside analgesics, although pain medicines have remained the central focus of its corporate research and commercial strategy.
Cholesterol-lowering medicine
Crestor
Crestor is the brand name for rosuvastatin, a cholesterol-lowering medicine. Grünenthal acquired the product from AstraZeneca in 2020 as part of its expansion into established pharmaceutical products.
Endocrinology
Nebido
Nebido is a testosterone-based medicine used in the treatment of male hypogonadism. Grünenthal acquired the product from Bayer in 2022.
Gastrointestinal medicine
Movantik
Movantik contains naloxegol and is used for opioid-induced constipation. Grünenthal obtained the product through its 2024 acquisition of Valinor.
Historical sedative · 1957
Contergan
Contergan was Grünenthal's brand for thalidomide, marketed from 1957 as a sedative and for morning sickness. It was withdrawn in 1961 after its severe teratogenic effects became clear. It is a historical product and is not marketed by Grünenthal for its original use.
Controversies
2010
Versatis promotional-code breach
The UK's Prescription Medicines Code of Practice Authority found that material associated with Grünenthal's field teams promoted off-label use of Versatis and contained a misleading cost comparison. The company accepted an undertaking in the case.
2010
Allegation concerning tapentadol promotion
The UK medicines regulator received an allegation that Grünenthal promoted an unlicensed tapentadol product to health professionals. Grünenthal investigated and concluded that the allegation was unsubstantiated.
1957
Thalidomide and the Contergan disaster
Grünenthal marketed thalidomide as Contergan after inadequate assessment of its effects during pregnancy. Exposure caused fetal deaths, miscarriages and severe congenital disabilities in many countries. The medicine was withdrawn in 1961, followed by criminal proceedings, compensation arrangements, regulatory reform and decades of criticism concerning the company's response to victims.
Marketing campaigns
- 2004EFIC-Grünenthal Grant
International
Grünenthal began supporting the EFIC-Grünenthal Grant to fund young scientists conducting pain research. The program provides project bursaries and has been described as one of the largest awards in its field.
Outcome. The grant became a continuing research-support initiative associated with pain science and early-career investigators.
- 1998Grünenthal Foundation for Palliative Medicine
Germany
The company launched a foundation to support palliative medicine and related clinical and academic development.
Outcome. With foundation support, an academic chair and palliative-care clinic were established at RWTH Aachen University in 2010.
Brand decisions
2024
Acquisition of Valinor and MovantikM&ABackground
Grünenthal continued using acquisitions to expand its commercial medicines platform.
Action taken
The company acquired Valinor and its naloxegol product Movantik.
Aftermath
The transaction broadened Grünenthal's portfolio into treatment for opioid-induced constipation.
2022
Acquisition of NebidoM&ABackground
Grünenthal continued expanding its established-medicines portfolio beyond core analgesics.
Action taken
The company acquired Nebido from Bayer.
Aftermath
The transaction added a testosterone-based endocrinology product used in hypogonadism treatment.
2019
Concentration of research on pain conditionsStrategyBackground
Grünenthal sought to align its research and development activity with its established expertise in pain treatment.
Action taken
The company prioritized peripheral neuropathic pain, chronic postoperative pain, osteoarthritis and chronic back pain, including investigation of newer approaches such as cell therapy.
Aftermath
The strategy reinforced pain management as the company's principal research and positioning focus.
2008
Additional contribution to the Thalidomide FoundationOtherBackground
Victims and campaigners continued to seek greater financial support decades after the original compensation arrangements.
Action taken
Grünenthal announced a voluntary €50 million contribution to the Thalidomide Foundation.
Aftermath
The payment was intended to improve the living conditions of thalidomide victims, although disputes over compensation continued.
Voluntary contribution. €50 million (2008)
1961
Withdrawal of ConterganOtherBackground
Evidence accumulated that thalidomide exposure during pregnancy was responsible for severe fetal injuries.
Action taken
Grünenthal withdrew Contergan from the market in late 1961.
Aftermath
The withdrawal became a central event in the thalidomide disaster and contributed to stronger pharmaceutical testing requirements.
Recent events
Grünenthal announces acquisition of Mestex AG[3]
Reported:
Grünenthal announced that it had acquired Mestex AG through the takeover of all of its shares and options, securing global rights to the investigational medicine MTX-071.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/grünenthal-gmbh · Editorial policy · How profiles are compiled